These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 34212073)

  • 21. Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy.
    Hou W; Yang B; Zhu H
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
    Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
    Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?
    Jiang B; Zhou L; Lu J; Wang Y; Liu C; You L; Guo J
    Front Oncol; 2020; 10():576399. PubMed ID: 33178608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC.
    Cattolico C; Bailey P; Barry ST
    Front Cell Dev Biol; 2022; 10():816517. PubMed ID: 35273962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.
    J Gunderson A; Rajamanickam V; Bui C; Bernard B; Pucilowska J; Ballesteros-Merino C; Schmidt M; McCarty K; Philips M; Piening B; Dubay C; Medler T; Newell P; Hansen P; Tran E; Tang E; Bifulco C; Crittenden M; Gough M; Young KH
    Oncoimmunology; 2021 Mar; 10(1):1900635. PubMed ID: 33796412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel systemic treatment approaches for metastatic pancreatic cancer.
    Dorman K; Heinemann V; Kobold S; von Bergwelt-Baildon M; Boeck S
    Expert Opin Investig Drugs; 2022 Mar; 31(3):249-262. PubMed ID: 35114868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.
    Yang J; Zhang Q; Wang J; Lou Y; Hong Z; Wei S; Sun K; Wang J; Chen Y; Sheng J; Su W; Bai X; Liang T
    EBioMedicine; 2022 Apr; 78():103958. PubMed ID: 35316682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression.
    Grage-Griebenow E; Jerg E; Gorys A; Wicklein D; Wesch D; Freitag-Wolf S; Goebel L; Vogel I; Becker T; Ebsen M; Röcken C; Altevogt P; Schumacher U; Schäfer H; Sebens S
    Mol Oncol; 2014 Jul; 8(5):982-97. PubMed ID: 24746181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Partial ligand shielding nanoparticles improve pancreatic ductal adenocarcinoma treatment via a multifunctional paradigm for tumor stroma reprogramming.
    Zhao T; Zhang R; He Q; Zhou H; Song X; Gong T; Zhang Z
    Acta Biomater; 2022 Jun; 145():122-134. PubMed ID: 35381402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma.
    Li Q; Qin S; Tian H; Liu R; Qiao L; Liu S; Li B; Yang M; Shi J; Nice EC; Li J; Lang T; Huang C
    Small; 2023 Jun; 19(23):e2207201. PubMed ID: 36899444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of the stromal contribution to Sonic Hedgehog-dependent pancreatic adenocarcinoma.
    Damhofer H; Medema JP; Veenstra VL; Badea L; Popescu I; Roelink H; Bijlsma MF
    Mol Oncol; 2013 Dec; 7(6):1031-42. PubMed ID: 23998958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Looking Beyond Checkpoint Inhibitor Monotherapy: Uncovering New Frontiers for Pancreatic Cancer Immunotherapy.
    Gupta K; Giurini EF; Ralph O; Pappas SG
    Mol Cancer Ther; 2024 Sep; ():. PubMed ID: 39311547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
    Tarannum M; Vivero-Escoto JL
    Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC.
    Olaoba OT; Ligali FC; Alabi ZO; Akinyemi AO; Ayinde KS
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188483. PubMed ID: 33232723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer.
    Wandmacher AM; Letsch A; Sebens S
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors.
    Skelton RA; Javed A; Zheng L; He J
    J Surg Oncol; 2017 Jul; 116(1):55-62. PubMed ID: 28628715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of epigenetics in pancreatic ductal adenocarcinoma.
    Pandey S; Gupta VK; Lavania SP
    Epigenomics; 2023 Jan; 15(2):89-110. PubMed ID: 36647796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
    Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D
    Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.